AAP
FULC icon

Arax Advisory Partners’s Fulcrum Therapeutics FULC Stock Holding History

Arax Advisory Partners’s Portfolio FULC Stock Details FULC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$852 Sell
111
-70
-39% -$649 ﹤0.01% 3329
2025
Q4 		$2.05K Buy
+181
New +$1.84K ﹤0.01% 3249

Other funds holding FULC

SCM
Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return
B
Braidwell Stamford, Connecticut $3B AUM 46.72% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
SL
Siren LLC Greenwich, Connecticut $3.61B AUM 203.3% 1-Year Est. Return
FTM
First Turn Management Del Mar, California $895M AUM 261.28% 1-Year Est. Return
Aberdeen Group
Aberdeen Group Edinburgh, United Kingdom $61.9B AUM 29.81% 1-Year Est. Return

Arax Advisory Partners's FULC Position: Q1 2026 in Review

Arax Advisory Partners reduced its Fulcrum Therapeutics (FULC) stake by 39% in Q1 2026, selling an estimated $649 and leaving 111 shares worth $852. The position accounts for ﹤0.01% of the portfolio, ranked #3329.

Arax Advisory Partners first reported a position in FULC in Q4 2025 and has held it in 2 quarters since. The position peaked at $2.05K in Q4 2025. 169 funds tracked by Wall St. Rank hold FULC as of Q1 2026.

  • Arax Advisory Partners held 111 shares of Fulcrum Therapeutics worth $852 as of Q1 2026.
  • Arax Advisory Partners sold 70 Fulcrum Therapeutics shares in Q1 2026, an estimated $649.
  • Fulcrum Therapeutics made up ﹤0.01% of Arax Advisory Partners's portfolio in Q1 2026, its #3329 holding.
  • Arax Advisory Partners first reported a position in Fulcrum Therapeutics in Q4 2025 and has held it in 2 quarters since.
  • Arax Advisory Partners's Fulcrum Therapeutics position peaked at $2.05K in Q4 2025.
  • 169 funds tracked by Wall St. Rank held Fulcrum Therapeutics as of Q1 2026.

Based on Arax Advisory Partners's 13F filing for Q1 2026, filed 13 May 2026.